Seres Therapeutics Inc
F:1S90
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Seres Therapeutics Inc
F:1S90
|
US |
|
Taoweave Inc
NASDAQ:TWAV
|
US |
|
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS
IST:RTALB.E
|
TR |
|
G
|
Gap Inc
F:GAP
|
US |
|
Prodia Widyahusada Tbk PT
IDX:PRDA
|
ID |
|
Foxtons Group PLC
LSE:FOXT
|
UK |
|
Dai Nippon Printing Co Ltd
F:DNP0
|
JP |
|
A
|
Ardelyx Inc
F:41X
|
US |
|
Sonova Holding AG
OTC:SONVF
|
CH |
|
International Petroleum Corp
OTC:IPCFF
|
CA |
|
T
|
Triad Group PLC
SWB:TD8
|
UK |
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value for Seres Therapeutics Inc.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Seres Therapeutics Does
Seres Therapeutics is a biotechnology company that develops therapies based on the human microbiome, the community of bacteria that live in the body. Its main products are designed to restore a healthier balance of gut microbes, especially for patients whose intestinal bacteria have been disrupted by illness or antibiotic use. The company’s best-known work has focused on treating recurrent Clostridioides difficile infection, a serious gut infection that often comes back after standard antibiotics.
- Headquarters
- United States of America US
- Employees
- 66
- IPO date
- Jun 26, 2015
